<DOC>
	<DOCNO>NCT00874549</DOCNO>
	<brief_summary>Safety : To describe rate immediate reaction , solicit injection-site systemic reaction , unsolicited adverse event , serious adverse event follow vaccination either Menactra® vaccine Menomune® vaccine . Immunogenicity : To evaluate immune response serogroups A , C , Y , W-135 four study group .</brief_summary>
	<brief_title>Exploratory Trial Evaluate Safety Immunogenicity Menactra® Menomune® Vaccines Subjects ≥ 56 Years</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Ambulatory healthy , determined medical history . 56 year age old time vaccination . Signed Institutional Review Board ( IRB ) approve informed consent form . Able attend schedule visit comply trial procedure . For woman , inability become pregnant negative urine pregnancy test time enrollment . Any condition , opinion Investigator , would pose health risk participant interfere evaluation vaccine . Serious chronic disease ( i.e. , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric , etc ) unstable might 1 ) interfere ability participate fully study 2 ) interfere evaluation vaccine . Known suspect impairment immunologic function . Febrile illness within last 72 hour oral temperature ≥ 100.4ºF time inclusion . History document invasive meningococcal disease previous meningococcal vaccination . Known suspected receipt diphtheriacontaining vaccine within precede 2 year . Administration immune globulin blood product within last three month , injected oral corticosteroid immunomodulator therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Systemic antibiotic therapy within 72 hour prior collection blood sample . Received vaccine 28day period prior enrollment schedule receive vaccination Visit 2 Groups 1 2 Visit 3 Groups 3 4 . Influenza vaccine may receive 2 week study vaccination . Suspected known hypersensitivity latex component either Menactra® vaccine Menomune® vaccine . Previous personal history GuillainBarré syndrome . Not available entire study period unable attend schedule visit comply study procedure . In female childbearing potential , positive equivocal urine pregnancy test enrollment . A nursing mother . Participation another interventional clinical trial 4 week precede enrollment planning participate another interventional clinical trial plan period study . Current use alcohol recreational drug may interfere subject 's ability comply trial visit procedure . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent .</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Meningococcal Vaccine</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Menomune®</keyword>
</DOC>